The record surge in prescriptions of GLP-1 drugs for patients without diabetes showed no signs of slowing through the first half of 2023 The pharmacological weight loss trend of the decade is still making headlines as Ozempic and other GLP-1 drugs continue to grow in popularity among people without diabetes who want to lose weight
Lieb, W., Enserro, D
evaluated the 2-week effect of liraglutide in a high-fat (60%), high-cholesterol (1.25%), and high-cholic acid (0.5%) along with hydroxypropyl--cyclodextrin (2%) in drinking water (HFCC-CDX) dietary mouse model of NASH and demonstrated that liraglutide decreased caloric intake and body weight and improved insulin resistance
Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro is the first dual-target therapy that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar levels while promoting weight loss
Peptides support aging, wellness, recovery, sleep, metabolism, and sexual health
The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size
